Cargando…

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galvano, Antonio, Scaturro, Dalila, Badalamenti, Giuseppe, Incorvaia, Lorena, Rizzo, Sergio, Castellana, Luisa, Cusenza, Stefania, Cutaia, Sofia, Santini, Daniele, Guadagni, Fiorella, Roselli, Mario, Gori, Stefania, Latteri, Mario Adelfio, Bazan, Viviana, Giulia, Letizia Mauro, Russo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700425/ https://www.ncbi.nlm.nih.gov/pubmed/31440444 http://dx.doi.org/10.1016/j.jbo.2019.100252

Ejemplares similares

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer
por: Ferroni, Patrizia, et al.
Publicado: (2021)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
por: Riondino, Silvia, et al.
Publicado: (2019)

Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress
por: Ferroni, Patrizia, et al.
Publicado: (2015)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinoma: a case report
por: Sandonato, Luigi, et al.
Publicado: (2009)

Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology
por: Ferroni, Patrizia, et al.
Publicado: (2017)

Breast Cancer Prognosis Using a Machine Learning Approach
por: Ferroni, Patrizia, et al.
Publicado: (2019)

Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care
por: Riondino, Silvia, et al.
Publicado: (2020)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Secretory breast carcinoma with metastatic sentinel lymph node
por: Vieni, Salvatore, et al.
Publicado: (2006)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022)

Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Russo, Valentina, et al.
Publicado: (2022)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer
por: Cipolla, Calogero, et al.
Publicado: (2021)

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
por: Norata, Davide, et al.
Publicado: (2023)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
por: Dimino, Alessandra, et al.
Publicado: (2022)

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Prognostic value of glycated hemoglobin in colorectal cancer
por: Ferroni, Patrizia, et al.
Publicado: (2016)

Mitochondrion at the Crossroad Between Nutrients and Epigenome
por: Taormina, Giusi, et al.
Publicado: (2019)

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin
por: Rizzo, Sergio, et al.
Publicado: (2017)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_phth6djnsnk8p536oan820j0l2